Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
复制标题
DOI：
10.1056/nejmoa0904554
复制
发表时间：
2009-09-03
影响因子：
158.5
通讯作者：
Taron, Miquel
中科院分区：
文献类型：
--
作者：
Rosell, Rafael;Moran, Teresa;Taron, Miquel
背景资料：表皮生长因子受体基因（EGFR）激活突变导致晚期非小细胞肺癌患者对酪氨酸激酶抑制剂吉非替尼和厄洛替尼超敏反应我们评估了大规模筛选EGFR突变的患者的可行性，并分析了突变和厄洛替尼treatment.Methods的结果之间的关联：从2005年4月至2008年11月，从2105例患者在129个机构在西班牙的肺癌进行了EGFR突变的筛选。分析在中心实验室进行。结果：2105例患者中，EGFR基因突变350例（16.6%）。突变在女性（69.7%）、从不吸烟的患者（66.6%）和腺癌患者（80.9%）中更常见（P
Background: Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment.Methods: From April 2005 through November 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations. The analysis was performed in a central laboratory. Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment.Results: EGFR mutations were found in 350 of 2105 patients (16.6%). Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P